Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to $205.0 million.

  • Foghorn Therapeutics' Liabilities and Shareholders Equity fell 33.53% to $205.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $973.9 million, marking a year-over-year decrease of 17.32%. This contributed to the annual value of $284.0 million for FY2024, which is 0.68% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $205.0 million for Q3 2025, which was down 9.40% from $226.2 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Liabilities and Shareholders Equity ranged from a high of $519.8 million in Q4 2021 and a low of $186.1 million during Q3 2021.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $285.9 million (2023), whereas its average is $288.9 million.
  • Per our database at Business Quant, Foghorn Therapeutics' Liabilities and Shareholders Equity skyrocketed by 133.21% in 2022 and then crashed by 33.53% in 2025.
  • Quarterly analysis of 5 years shows Foghorn Therapeutics' Liabilities and Shareholders Equity stood at $519.8 million in 2021, then declined by 22.10% to $404.9 million in 2022, then decreased by 29.38% to $285.9 million in 2023, then fell by 0.68% to $284.0 million in 2024, then crashed by 33.53% to $205.0 million in 2025.
  • Its Liabilities and Shareholders Equity was $205.0 million in Q3 2025, compared to $226.2 million in Q2 2025 and $258.7 million in Q1 2025.